Table 11 Incidence of non-hematological adverse effects with different neoadjuvant treatment regimens
|  | Cisplatin alone | Carboplatin + anthracycline + taxane | Carboplatin + taxane | Carboplatin + Gemcitabine + PARPi | Carboplatin + NACT + PARPi | Carboplatin + NACT + anti VEGF antibody | PARPi | Carboplatin + Eribulin |
|---|---|---|---|---|---|---|---|---|
n | 196 | 106 | 239 | 93 | 398 | 1246 | 52 | 30 |
Adverse effect | ||||||||
 Gastrointestinal disorders | 4.6% | 2.8% | 8.4% | 24.7% | 6.5% | 27.7% | 0.0% | 0.0% |
 Cardiac disorders | 1.5% | 0.0% | 0.4% | 1.1% | 0.8% | 6.7% | 0.0% | 0.0% |
 Nervous system disorders | 0,.0% | 2.8% | 1.3% | 2.2% | 0.8% | 1.5% | 0.0% | 0.0% |
 Renal and urinary disorders | 1,.0% | 0.0% | 0.4% | 1.1% | 0.0% | 4.8% | 0.0% | 3.3% |
 Skin and subcutaneous tissue disorders | 1.0% | 0.0% | 0.8% | 0.0% | 0.0% | 7.1% | 0.0% | 0.0% |